Join us on 12-15-2022 for a live seminar about RNA SEQ
Join us on 12-15-2022 for a live seminar about RNA SEQ
These Terms of Use, effective November 1, 2019, set out how Alloy Therapeutics, Inc. (“Alloy”) uses and protects any information you provide when using this web site. If you have questions regarding our Terms of Use, please contact us directly.
This web site is owned and operated by Alloy. Unless otherwise specified, all materials on this web site are the property of Alloy and are protected by the copyright laws of the United States and worldwide by applicable copyright laws. You may view, print and download one copy of the materials from this web site on any single computer solely for your personal, informational, non-commercial use, provided you keep intact all copyright and other proprietary notices. No material published by Alloy on this web site, in whole or in part, may be copied, reproduced, modified, republished, uploaded, posted, transmitted, or distributed in any form or by any means without prior written permission from Alloy. The use of any such material on any other web site or networked computer environment or for any other purpose is strictly prohibited and such unauthorized use may violate copyright, trademark, and other similar laws.
Except for any disclosure by you for technical support purposes, all communications from you to this web site are considered non-confidential and non-proprietary. You agree that any and all comments, information, feedback and ideas regarding our company and solutions that you communicate to Alloy will be deemed, at the time of the communication to Alloy, the property of Alloy and Alloy shall be entitled to full rights of ownership, including without limitation, unrestricted right to use or disclose such feedback in any form, medium or technology now known or later developed, and for any purpose, commercial or otherwise, without compensation to you. You are solely responsible for the content of your communications and their legality under all laws and regulations. You agree not to use this web site to distribute, link to or solicit content that is defamatory, harassing, unlawful, libelous, harmful to minors, threatening, obscene, false, misleading, or infringing a third party intellectual or privacy rights.
The trademarks, service marks, and logos of Alloy used in this web site are the property of Alloy. You have no right to use any such trademarks, and nothing contained in this web site or the Terms of Use grants any right to use by implication, waiver, estoppel or otherwise any trademarks without the prior written permission of Alloy.
Alloy is not responsible for supplying content or materials from the web site that have expired or been removed. The materials provided at this web site are provided “as is” and any warranty express or implied, condition or other term of any kind, including without limitation, any warranty of merchantability, fitness for a particular purpose, non-infringement or title is hereby excluded.
These Terms of Use are governed by the law in force in the Commonwealth of Massachusetts, and the parties irrevocably submit to the non-exclusive jurisdiction of the courts of Massachusetts and courts of appeal from them for determining any dispute concerning the Terms of Use.
Our web site may contain links that enable you to visit other web sites of interest easily. Once you use these links to leave our site, you should know that we do not have any control over that other web site. We cannot be responsible for the protection and privacy of any information that you provide while visiting such sites and such sites are not governed by these Terms of Use. You should exercise caution and look at the privacy statement applicable to the web site in question.
Explore:
Our research facilities:
Boston, MA
Cambridge, UK
Basel, CH
Athens, GA
© 2023 Alloy Therapeutics, Inc. All Rights Reserved.
Thanks for your interest in our white paper, Targeting GPCRs with DeepImmune Antibody Discovery.
G protein-coupled receptors (GPCRs) play a central role in multiple physiological functions, from endocrine sensing to neurotransmission to chemotaxis of immune cells. This class has long been an attractive target for novel antibody drug discovery campaigns in multiple disease indications, but their unique nature produces many challenges for in vivo antibody discovery. In this white paper, we detail how our humanized mouse discovery platform, the ATX-Gx™, have been successfully utilized for GPCR-targeted antibody discovery, Alloy Antibody Discovery’s DeepImmune™ module builds on this robust in vivo discovery platform, coupling best-in-class immunogen production with multiple binder recovery approaches, and advanced machine-learning-based techniques for lead identification and optimization.
I’d like more material about Keyway TCR Discovery
Thanks for your interest in our recent Keyway TCRm Discovery webinar, Increasing Target Specificity and Tackling Intracellular Targets for TCRm Therapeutics Development with Keyway’s TCRm Discovery Offering. In it, the team at the helm of our TCR mimic discovery campaigns shared:
1. An overview of common challenges to intracellular protein-targeting drug discovery
2. Keyway’s industry-leading solutions to TCRm/TCR-based therapeutic discovery including its proprietary specificity screening and high-quality pMHC complex antigen production capabilities
3. A case study featuring the discovery of a panel of highly specific, functional TCRm binders against an intracellular immuno-oncology target
Upon filling out this form, you will receive an email with a link to the webinar recording.
